Cancer Immunotherapy: Macrophage-Mediated Phagocytosis

Tumor Associated Macrophages

Macrophages are important effector cells of innate immunity. Depending on the tissue microenvironment, tumor-associated macrophages (TAM) can differentiate into either cytotoxic (M1) or tumor-promoting (M2) states. While cytotoxic M1 macrophages are typically induced by IFN-γ alone or in concert with microbial products, tumor promoting M2 macrophages are induced by IL-4 or IL-13, IL-10, IL-21, TGFβ, immune complexes, and glucocorticoids.

Application Highlight: M1 Macrophage-Mediated Tumor Cell Killing

In a recent study the secreted glycoprotein thrombospondin 1 (TSP1) was shown to be a positive modulator of innate antitumor immunity by increasing M1 macrophage recruitment and stimulating reactive oxygen species (ROS)-mediated tumor cell killing. These conclusions were drawn, in part, by using xCELLigence RTCA impedance monitoring to evaluate the effect of TSP1 on macrophage/monocyte activity when co-cultured with MDA-MB-231 breast adenocarcinoma target cells. The % cytolysis data clearly indicate that the tumoricidal activity of both differentiated U937 human monocytes (left panel) and activated ANA-1 murine macrophages (right panel) are enhanced in the presence of TSP1.

Macrophage-Mediated Phagocytosis

Secreted glycoprotein TSP1 increases macrophage/monocyte-mediated tumoricidal activity.  MDA-MB-231 breast adenocarcinoma target cells were seeded in ACEA’s electronic microtiter plates (E-Plates) and incubated for up to 24 hours. Differentiated U937 human monocytes (left panel) or activated ANA-1 murine macrophages (right panel) were then added in the presence or absence of soluble TSP1. Figure adapted from Cancer Res. 2008;68(17):7090-9.  Note that the RT-CES® described in this publication was ACEA’s first generation real-time cell analysis (RTCA) system, and has subsequently been rebranded as xCELLigence RTCA.

Key Benefits of Using xCELLigence To Study Bispecific Antibodies/BiTEs:
  1. Label-Free: Allowing for more physiological assay conditions; labeling or secondary assays aren’t required.
  2. Real-Time: Quantitative monitoring of both fast (hours) and slow (days) killing kinetics.
  3. Sensitive: Capable of evaluating low effector cell to target cell ratios that are physiologically relevant.
  4. Simple Workflow: Requires only the addition of effector cells to target cells (in the presence or absence of antibodies); homogeneous assay without additional sample handling.
  5. Automatic Data Plotting: RTCA software enables facile data display and objective analysis, precluding the subjective data vetting that is common to imaging-based assays.

IMT Handbook

Explore Functional Potency Assays for Cancer Immunotherapy Research

  • Antibody-Dependent Cell-Mediated Cytolysis (ADCC)
  • BiTEs and Bispecific Antibodies
  • Checkpoint Inhibitors
  • CAR-T Cells

Download Handbook
Test Alt

Cancer Immunotherapy Research Grant 

The research grant winner will be provided access to the xCELLigence Real Time Cell Analysis (RTCA) SP instrument, consumables, and consultation for up to 6 months. Apply by December 15, 2019.

Learn More
Test Alt

WEBINAR –The Next Generation of CAR-T Cells: New Techniques in Gene Editing and Rapid Assessment with Real Time Live Cell Analysis 

Watch our experts in CAR-T cell development as they discuss new techniques to further improve functionality.

Watch Now

Macrophage-mediated phagocytosis – Supporting Information:
  • Adherent target cells tested:
    MDA-MB-231, MDA-MB-435, MCF-7
  • Macrophage-Mediated Phagocytosis – Compatible xCELLigence Systems:
3×16 wells1×96 wells6×96 wellsUp to 4×384 wells
  • References:
  1. Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Martin-Manso G, Galli S, Ridnour LA, Tsokos M, Wink DA, Roberts DD. Cancer Res. 2008 Sep 1;68(17):7090-9. (National Institutes of Health, USA)
  2. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Cook KL, Wärri A, Soto-Pantoja DR, Clarke PA, Cruz MI, Zwart A, Clarke R. Clin Cancer Res. 2014 Jun 15;20(12):3222-32. (Georgetown University Medical Center, USA)